Berita English News

Novartis Wins US Approval for Targeted Cancer Drug Combination

Kamis, 23 Juni 2022 | 16:38 WIB
Novartis Wins US Approval for Targeted Cancer Drug Combination

ILUSTRASI. A targeted oral drug combination by Novartis won US approval for use in a wide range of advanced solid tumours that are driven by a certain genetic contributor. REUTERS/Arnd Wiegmann/File Photo

Sumber: Reuters | Editor: Anastasia Lilin Yuliantina

KONTAN.CO.ID - FRANKFURT. A targeted oral drug combination by Novartis won US approval for use in a wide range of advanced solid tumours that are driven by a certain genetic contributor, widening the use of a novel treatment approach that is known as tumour agnostic.

The Food and Drug Administration early on Thursday granted accelerated approval for the combination of the two drugs Tafinlar and Mekinist for adults and children as young as six with inoperable or metastatic solid tumours with a mutation known as BRAF V600, who have exhausted other treatment options.


Baca juga